Navigation Links
Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
Date:10/13/2008

upplied to Boston Scientific as part of a distribution agreement between the two companies.

Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its anti-proliferative properties.

Additional information about XIENCE V, including important safety and effectiveness information, is available online at http://www.xiencev.com.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products.

About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
3. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
4. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
5. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
6. Dynavaxs HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
9. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
10. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
11. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 Tandem Diabetes Care®, Inc. (NASDAQ: ... of the t:slim® Insulin Pump, today reported its financial results ... In comparing the second quarter of 2014 to the same ... $10.3 million from $5.5 million , t:slim Pump shipments ... In comparing six months ended June 30, 2014 to ...
(Date:7/31/2014)... SUNNYVALE, Calif., July 31, 2014 Pharmacyclics, Inc. (the ... and recent developments for the quarter ended June 30, 2014. ... Ended June 30, 2014 Revenue Total revenue for the ... $54.7 million for the quarter ended June 30, 2013 primarily ... $109.5 million. Total revenue for the six ...
(Date:7/31/2014)... SAN FRANCISCO, July 31, 2014 Nektar Therapeutics (Nasdaq: ... the second quarter ended June 30, 2014. ... were $301.4 million as compared to $309.1 million at March ... time for Nektar as we look forward to significant milestones ... W. Robin, President and Chief Executive Officer of Nektar. "The ...
Breaking Medicine Technology:Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4
... ANDOVER, Mass., June 23, 2011 Smith & Nephew, Inc., ... SNN ) (London Stock Exchange: SN) announced today ... found in Smith & Nephew,s favor that Arthrex, Inc., (Naples, ... exclusively licensed to Smith & Nephew. The ...
... Mr. Ronald L. Chez, a private investor, filed an amended ... RGEN ) with the SEC. RepliGen Corporation ... integrated company by developing and marketing innovative drugs that deliver ... and gastroenterology.  RepliGen has a core competency in the development ...
Cached Medicine Technology:Smith & Nephew Endoscopy Awarded $85 Million in Patent Infringement Case Against Arthrex, Inc. 2Smith & Nephew Endoscopy Awarded $85 Million in Patent Infringement Case Against Arthrex, Inc. 3
(Date:8/2/2014)... On July 21, 2014, the Johns Hopkins Health System ... the class action lawsuit filed October 24, 2013, ... MM, on behalf of thousands of women who allegedly were ... According to The Baltimore Sun , the $190 million ... physician accused of sexual misconduct. , An investigation prompted by ...
(Date:8/1/2014)... August 02, 2014 Although most people ... their teeth and gums, it is particularly important for ... gum disease in two different ways. Hormones can affect ... difficult for these tissues to receive nutrients essential to ... the body responds to toxins produced by plaque bacteria, ...
(Date:8/1/2014)... The Judicial Panel on Multidistrict Litigation (JPML) ... caused strokes, heart attacks, and other injuries in men ... Kennelly as the transferee judge and ordered what could ... court. , As one of his first organizing acts, ... attorneys who will move the litigation forward on behalf ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Parker Waichman ... rights of victims injured by defective medical devices and ... be recalling its Ethicon surgical power morcellator devices used ... sited concerns involving the spread of cancer associated with ... dated July 31, 2014. , Johnson & Johnson ...
(Date:8/1/2014)... Almost 140 people die every year in accidents ... But there are several simple ways to ... coordinator at Cincinnati Children,s Hospital Medical Center,s Comprehensive ... news release. "As families begin to prepare ... parents and children to go over school bus ...
Breaking Medicine News(10 mins):Health News:Baltimore Lawyer Steven H. Heisler Urges Victims of OB/GYN Misconduct to Speak Out 2Health News:Baltimore Lawyer Steven H. Heisler Urges Victims of OB/GYN Misconduct to Speak Out 3Health News:Midtown Dentistry Renews Call for Women to Look After Their Dental Health 2Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 2Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 3Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 4Health News:Expert Offers School Bus Safety Tips 2
... had been in the forefront, monitoring the Herculean task of ... the documentation of the dealers. // This is being done ... is still in safe custody. 20 teams comprising of officials ... with local civic officials. ,The teams will be ...
... in Hong Kong and China have identified the deadly H5N1 ... markets of Southern China, sparking fears of bird flu pandemic//. ... hosts of the bird flu virus. This however is the ... detected among seemingly healthy chickens. Infected chickens usually die within ...
... 'in'? A new report by the American Medical Association has ... wild (s) ways!// ,A survey of 644 female college ... berserk is their take on having fun in life. Three out ... for outrageous behavior- spring break drinking meant bingeing on booze, getting ...
... for a probable influenza pandemic, and its effects on 2.6 ... concern and at a press conference , Health Minister Philippe// ... the beginning of the epidemic we're able to limit the ... plan ready, to face a worst-case possibility, of the initial ...
... It's been a long haul from a medical college here ... becoming the only Indian-born radiologist// licensed to privately practise in ... in his specialty along the way., ,He sees up ... p.m. and then writes up the reports, a task that ...
... means just tough whole-grain products. The movement has burst out ... are available that would have been unthinkable a few years ... whole-grain muesli, rubbery tofu and tasteless vegetarian cutlets, but times ... of Europe today, you will find organic ice cream and ...
Cached Medicine News:Health News:Healthy, Bird Flu Infected Chickens In Chinese Markets 2Health News:Indian-Born Doctor Diddy Shines In Germany 2Health News:Organic food loses its whole-grain image 2
... a two-piece Titanium (Ti-6Al-4V) screw offered in ... variety of lengths. The two pieces are ... packaged. A single instrument set contains all ... both Standard and Mini Kompressor Compression Screws. ...
... Avanta Total Wrist is designed ... in patients suffering from rheumatoid, ... The implant is designed as ... bone resection and aiding in ...
... Within the last decade KMI® revolutionized the ... the Universal Total Wrist System. We're at ... next generation product, the Universal2. Like the ... the way patients live with debilitating arthritis. ...
... NeedlePunch is a simple, effective instrument to grasp ... FiberWire stitch and loop. The grasping function of ... soft tissue and precisely place a stitch up ... the tissue, all in one quick step. The ...
Medicine Products: